These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36099796)

  • 41. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.
    Niu Y; Chang TM; Yeh S; Ma WL; Wang YZ; Chang C
    Oncogene; 2010 Jun; 29(25):3593-604. PubMed ID: 20440270
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estrogen receptor β regulates AKT activity through up-regulation of INPP4B and inhibits migration of prostate cancer cell line PC-3.
    Chaurasiya S; Wu W; Strom AM; Warner M; Gustafsson JÅ
    Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26347-26355. PubMed ID: 33020300
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer.
    Abbasi A; Movahedpour A; Amiri A; Najaf MS; Mostafavi-Pour Z
    Curr Mol Med; 2021; 21(4):332-346. PubMed ID: 32881669
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Independence of HIF1a and androgen signaling pathways in prostate cancer.
    Tran MGB; Bibby BAS; Yang L; Lo F; Warren AY; Shukla D; Osborne M; Hadfield J; Carroll T; Stark R; Scott H; Ramos-Montoya A; Massie C; Maxwell P; West CML; Mills IG; Neal DE
    BMC Cancer; 2020 May; 20(1):469. PubMed ID: 32450824
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Androgen Signaling in the Tumor Microenvironment.
    Özdemir BC
    Adv Exp Med Biol; 2021; 1270():169-183. PubMed ID: 33123999
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.
    Bogdanos J; Karamanolakis D; Tenta R; Tsintavis A; Milathianakis C; Mitsiades C; Koutsilieris M
    Endocr Relat Cancer; 2003 Jun; 10(2):279-89. PubMed ID: 12790789
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Determining the prognostic significance of IKKα in prostate cancer.
    Montes M; MacKenzie L; McAllister MJ; Roseweir A; McCall P; Hatziieremia S; Underwood MA; Boyd M; Paul A; Plevin R; MacKay SP; Edwards J
    Prostate; 2020 Oct; 80(14):1188-1202. PubMed ID: 33258506
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.
    Chen WY; Tsai YC; Yeh HL; Suau F; Jiang KC; Shao AN; Huang J; Liu YN
    Sci Signal; 2017 Aug; 10(492):. PubMed ID: 28811384
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells.
    Moritz T; Venz S; Junker H; Kreuz S; Walther R; Zimmermann U
    Tumour Biol; 2016 Aug; 37(8):10435-46. PubMed ID: 26846108
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
    Ebrahimi S; Hashemy SI; Sahebkar A; Aghaee Bakhtiari SH
    Curr Mol Pharmacol; 2021 Oct; 14(4):559-569. PubMed ID: 33357209
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer.
    McCarty MF; Hejazi J; Rastmanesh R
    Integr Cancer Ther; 2014 Sep; 13(5):386-95. PubMed ID: 24867960
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
    Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Estrogen Receptor Signaling Pathways Involved in Invasion and Colony Formation of Androgen-Independent Prostate Cancer Cells PC-3.
    Lombardi APG; Cavalheiro RP; Porto CS; Vicente CM
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503805
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.
    Harris AE; Metzler VM; Lothion-Roy J; Varun D; Woodcock CL; Haigh DB; Endeley C; Haque M; Toss MS; Alsaleem M; Persson JL; Gudas LJ; Rakha E; Robinson BD; Khani F; Martin LM; Moyer JE; Brownlie J; Madhusudan S; Allegrucci C; James VH; Rutland CS; Fray RG; Ntekim A; de Brot S; Mongan NP; Jeyapalan JN
    Front Endocrinol (Lausanne); 2022; 13():1006101. PubMed ID: 36263323
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.
    Nakazawa M; Kyprianou N
    J Steroid Biochem Mol Biol; 2017 Feb; 166():84-90. PubMed ID: 27189666
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of Androgen Receptor Signaling Promotes Prostate Cancer Cell Migration via Upregulation of Annexin A1 Expression.
    Yang W; Wang K; Ma J; Hui K; Lv W; Ma Z; Huan M; Luo L; Wang X; Li L; Chen Y
    Arch Med Res; 2021 Feb; 52(2):174-181. PubMed ID: 33059953
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation.
    Brown NE; Paluch AM; Nashu MA; Komurov K; Waltz SE
    Neoplasia; 2018 Sep; 20(9):917-929. PubMed ID: 30121008
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nanovectorization of Prostate Cancer Treatment Strategies: A New Approach to Improved Outcomes.
    Omabe K; Paris C; Lannes F; Taïeb D; Rocchi P
    Pharmaceutics; 2021 Apr; 13(5):. PubMed ID: 33919150
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
    Isikbay M; Otto K; Kregel S; Kach J; Cai Y; Vander Griend DJ; Conzen SD; Szmulewitz RZ
    Horm Cancer; 2014 Apr; 5(2):72-89. PubMed ID: 24615402
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Delineation of the androgen-regulated signaling pathways in prostate cancer facilitates the development of novel therapeutic approaches.
    Awad D; Pulliam TL; Lin C; Wilkenfeld SR; Frigo DE
    Curr Opin Pharmacol; 2018 Aug; 41():1-11. PubMed ID: 29609138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.